全文获取类型
收费全文 | 170468篇 |
免费 | 12798篇 |
国内免费 | 6825篇 |
专业分类
耳鼻咽喉 | 695篇 |
儿科学 | 3057篇 |
妇产科学 | 2241篇 |
基础医学 | 23825篇 |
口腔科学 | 2999篇 |
临床医学 | 15384篇 |
内科学 | 36476篇 |
皮肤病学 | 1930篇 |
神经病学 | 11249篇 |
特种医学 | 2765篇 |
外国民族医学 | 30篇 |
外科学 | 10344篇 |
综合类 | 25089篇 |
现状与发展 | 35篇 |
预防医学 | 13581篇 |
眼科学 | 1953篇 |
药学 | 21742篇 |
29篇 | |
中国医学 | 5391篇 |
肿瘤学 | 11276篇 |
出版年
2024年 | 357篇 |
2023年 | 1955篇 |
2022年 | 4681篇 |
2021年 | 6126篇 |
2020年 | 5037篇 |
2019年 | 5232篇 |
2018年 | 5242篇 |
2017年 | 5252篇 |
2016年 | 5826篇 |
2015年 | 6549篇 |
2014年 | 10615篇 |
2013年 | 12344篇 |
2012年 | 10902篇 |
2011年 | 11911篇 |
2010年 | 9267篇 |
2009年 | 8847篇 |
2008年 | 9064篇 |
2007年 | 9088篇 |
2006年 | 7975篇 |
2005年 | 7203篇 |
2004年 | 6035篇 |
2003年 | 5081篇 |
2002年 | 4010篇 |
2001年 | 3570篇 |
2000年 | 3014篇 |
1999年 | 2651篇 |
1998年 | 2304篇 |
1997年 | 2195篇 |
1996年 | 1818篇 |
1995年 | 1559篇 |
1994年 | 1455篇 |
1993年 | 1133篇 |
1992年 | 1015篇 |
1991年 | 902篇 |
1990年 | 724篇 |
1989年 | 600篇 |
1988年 | 531篇 |
1987年 | 517篇 |
1986年 | 440篇 |
1985年 | 947篇 |
1984年 | 959篇 |
1983年 | 713篇 |
1982年 | 742篇 |
1981年 | 655篇 |
1980年 | 583篇 |
1979年 | 477篇 |
1978年 | 394篇 |
1977年 | 324篇 |
1976年 | 350篇 |
1975年 | 330篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Wojciech Szychta M.D. Ph.D. Gheorghe Cerin M.D. Ph.D. F.E.S.C. Bogdan Adrian Popa M.D. Armienti Felice M.D. Guido Lanzillo M.D. Ph.D. Marco Diena M.D. Grzegorz Opolski M.D. Ph.D. F.E.S.C. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(6):1040-1043
Sinus venosus atrial septal defect (SV‐ASD) usually coexists with partial anomalous pulmonary vein connection (PAPVC). It is a difficult diagnosis in transthoracic echocardiography (TTE) due to eccentric position of defects. We present a rare case of atypical anatomical variation in PAPVC, which was never described before. Two right pulmonary veins drained into superior vena cava, which overrode SV‐ASD and interatrial septum, a third pulmonary vein into the right atrium. Complete diagnosis could not be set after TTE, nor transesophageal echocardiography, whereas angio‐CT was finally conclusive. This diagnostic approach allowed the surgical planning. 相似文献
12.
周蕾 《国际妇产科学杂志》2015,42(1):91-95
宫颈癌对妇女健康构成严重威胁,人乳头瘤病毒感染与宫颈病变及宫颈癌的发生密切相关。关于宫颈癌发生发展的机制仍在研究中。近年研究发现一种多功能核蛋白,即死亡结构域相关蛋白(death domain associated protein,Daxx),其与细胞内蛋白或病毒蛋白相互作用,参与调节细胞凋亡、转录调控、抗病毒等细胞活动,在不同途径中发挥不同的生理或病理作用。通过对Daxx功能及其作用机制的研究有助于进一步阐明宫颈癌发生发展的机制,有助于发现新的预防和治疗方法。综述Daxx的一般特性和研究现况及其在宫颈病变的研究进展。 相似文献
13.
《Médecine et maladies infectieuses》2020,50(6):525-527
BackgroundCampylobacter is the most common cause of infectious diarrhea in agammaglobulinemia patients. These infections can be severe, prolonged, and recurrent in such patients.Patient and methodsWe report a 29-year-old male patient with X-linked agammaglobulinemia with Campylobacter coli enterocolitis that persisted for nine months despite multiple 10- to 14-day courses of oral ciprofloxacin and azithromycin.ResultsThe isolate was highly resistant to ciprofloxacin, erythromycin, tetracycline, and fosfomycin. The patient failed to respond to intravenous ertapenem, 1.0 g/day for two weeks, to which the pathogen was susceptible. He was finally cured with oral gentamicin, 80 mg four times daily, and stool cultures remained negative during the seven-month follow-up.ConclusionOral aminoglycoside might be the most appropriate choice for eradication of persistent Campylobacter in the intestinal tract for macrolide- and fluoroquinolone-resistant isolate in agammaglobulinemia patients with chronic diarrhea or relapsing systemic infections. 相似文献
14.
15.
16.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
17.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
18.
19.
20.